文献速递哮喘

Tralokinumab治疗重度未控制哮喘:STRATOS 1与STRATOS 2两项随机双盲安慰剂对照3期试验

Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials.
PubMed 文献 · Lancet Respir Med · 2018-05-20

STRATOS 1和STRATOS 2评估抗IL-13单抗tralokinumab在重度未控制哮喘中的疗效与安全性。STRATOS 2在FeNO高人群中未显著改善AAER。结果不支持IL-13在重度哮喘急性发作中的关键作用。

核心结论

  • STRATOS 1中tralokinumab降低了基线FeNO≥37 ppb重度哮喘患者的AAER,但STRATOS 2中未重复该效果。
  • 这些不一致的AAER效应不支持IL-13在重度哮喘急性发作中起关键作用。

研究设计与样本

  • STRATOS 1和STRATOS 2为随机、双盲、平行组、安慰剂对照3期试验,纳入12-75岁重度哮喘患者。
  • 患者需吸入糖皮质激素(≥500 μg/日氟替卡松或等效)联合长效β2受体激动剂仍控制不佳,且未使用口服糖皮质激素。
  • STRATOS 1在14国246个中心进行,STRATOS 2在13国242个中心进行。
  • STRATOS 1随机分配(2:1)接受tralokinumab 300 mg或安慰剂皮下注射每2周或每4周,共52周。
  • STRATOS 2随机分配(1:1)接受tralokinumab 300 mg或安慰剂皮下注射每2周,共52周。

主要发现

  • STRATOS 1随机分配1207例,治疗1202例:每2周tralokinumab组398例,每4周组404例,安慰剂组400例。
  • STRATOS 2随机分配856例,治疗849例:每2周tralokinumab组427例,安慰剂组422例。

关键数值与推荐

  • STRATOS 1全体人群主要终点为第52周年化哮喘急性发作率(AAER)降低,未达到统计学显著。
  • STRATOS 1中基线FeNO≥37 ppb被确定为优选生物标志物,该亚组中每2周tralokinumab显著降低AAER。
  • STRATOS 2主要终点为FeNO高人群中第52周AAER降低,未达到统计学显著。

临床怎么用

  • 本试验结果不支持在重度未控制哮喘中常规使用tralokinumab。
  • FeNO≥37 ppb作为生物标志物的预测价值在两项试验间不一致,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tralokinumab is an anti-interleukin-13 human monoclonal antibody developed for the treatment of severe, uncontrolled asthma. These clinical trials aimed to assess the efficacy and safety of tralokinumab in this population. METHODS: STRATOS 1 and STRATOS 2 were randomised, double-blind, parallel-group, placebo-controlled, phase 3 clinical trials that enrolled participants aged 12-75 years with severe asthma that was inadequately controlled despite use of inhaled corticosteroids (≥500 μg per day fluticasone or equivalent) and a long-acting β2 agonist (but not oral corticosteroids). STRATOS 1 was done at 246 sites in 14 countries, and STRATOS 2 was done at 242 sites in 13 countries. In STRATOS 1, participants were randomly assigned (2:1) to receive tralokinumab 300 mg or matching placebo subcutaneously every 2 weeks or every 4 weeks for 52 weeks. In STRATOS 2, participants were randomly assigned (1:1) to receive tralokinumab 300 mg or matching placebo subcutaneously every 2 weeks for 52 weeks. STRATOS 1 attempted to identify a biomarker-positive population with enhanced tralokinumab benefit, which was then tested in STRATOS 2. The primary endpoint was the annualised asthma exacerbation rate (AAER) reduction at week 52 in the all-comers population for STRATOS 1 and in the biomarker-positive population for STRATOS 2. All efficacy analyses for both trials were done on the full analysis set by an intention-to-treat approach. The safety analysis set comprised any participant who received the investigational drug and was categorised by treatment received. These trials are registered with ClinicalTrials.gov, numbers NCT02161757 (STRATOS 1) and NCT02194699 (STRATOS 2), and with the EU Clinical Trials Register, EudraCT 2013-005614-35 (STRATOS 1) and EudraCT 2013-005615-27 (STRATOS 2). FINDINGS: STRATOS 1 was done between June 13, 2014, and Feb 28, 2017. 1207 participants were randomly assigned and 1202 treated as follows: tralokinumab every 2 weeks (n=398), tralokinumab every 4 weeks (n=404), or placebo (n=400). STRATOS 2 was done between Oct 30, 2014, and Sept 21, 2017. 856 participants were randomly assigned and 849 treated as follows: tralokinumab every 2 weeks (n=427) and placebo every 2 weeks (n=422). In the STRATOS 1 all-comers population, tralokinumab every 2 weeks did not significantly reduce AAER compared with placebo (7·0% reduction [95% CI -20·8 to 28·4]; rate ratio 0·93 [95% CI 0·72 to 1·21]; p=0·59). Baseline fractional exhaled nitric oxide (FENO) 37 ppb or greater was identified as the preferred biomarker in STRATOS 1; in FENO-high participants, tralokinumab every 2 weeks (n=97) reduced AAER by 44·0% (95% CI 6·0 to 66·0; rate ratio 0·56 [95% CI 0·34 to 0·94]; p=0·028) compared with placebo (n=102). In the STRATOS 2 FENO-high population, tralokinumab every 2 weeks (n=108) did not significantly improve AAER (15·8% reduction [95% CI -33·7 to 47·0]; rate ratio 0·84 [95% CI 0·53 to 1·34]; p=0·47) compared with placebo (n=121). The safety profile was consistent with that of previous tralokinumab trials. INTERPRETATION: Tralokinumab reduced AAER in participants with severe asthma with baseline FENO 37 ppb or higher in STRATOS 1, but not in STRATOS 2. These inconsistent effects on AAER do not support a key role for interleukin 13 in severe asthma exacerbations. FUNDING: AstraZeneca.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Panettieri RA, Sjöbring U, Péterffy A, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med. 2018. PMID: 29792288. doi:10.1016/S2213-2600(18)30184-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。